Haemophilus influenzae type b meningitis in a vaccinated and immunocompetent child  by Almeida, Ana Filipe et al.
JJ
S
H
m
i
A
M
a
4
b
A
R
J
a
h
1ARTICLE IN PRESSIPH-600; No. of Pages 4
ournal of Infection and Public Health (2016) xxx, xxx—xxx
HORT COMMUNICATION
aemophilus  inﬂuenzae  type  b
eningitis  in  a  vaccinated  and
mmunocompetent  child
na  Filipe  Almeidaa,∗,  Eunice  Trindadea,  Artur  B.  Vitorb,
argarida  Tavaresb
Department  of  Pediatrics,  São  João  Hospital,  Alameda  Prof.  Hernâni  Monteiro,
200-319 Porto,  Portugal
Department  of  Pediatrics,  Infectious  Diseases  Unit,  São  João  Hospital,
lameda Prof.  Hernâni  Monteiro,  4200-319  Porto,  Portugal
eceived  24  March  2016;  received  in  revised  form  27  May  2016;  accepted  24  June  2016
KEYWORDS
Haemophilus
inﬂuenzae  type  b;
Meningitis;
Haemophilus
inﬂuenzae  type  b
vaccine;
Vaccine  failure;
Children
Abstract  Invasive  Haemophilus  inﬂuenzae  type  b  (Hib)  disease  decreased  dramati-
cally  after  the  introduction  of  conjugate  vaccine  in  routine  immunization  schedules.
We  report  a  case  of  a  ﬁfteen-months-old  girl,  previously  healthy  and  vaccinated,
admitted  in  the  emergency  room  with  fever  and  vomiting.  She  was  irritable  and
the  Brudzinski’s  sign  was  positive.  The  cerebrospinal  ﬂuid  (CSF)  analysis  showed
pleocytosis  and  high  protein  level.  Empiric  intravenous  antibiotics  (ceftriaxone  and
vancomycin)  were  administered  for  suspected  bacterial  meningitis  during  10  days.
Serotyping  of  the  Haemophilus  inﬂuenzae  strain  found  in  CSF  revealed  a  serotype
b.  After  one  year  of  follow-up  no  Hib  meningitis  sequelae  were  noted.
Despite  vaccination  compliance  and  absence  of  risk  factors,  invasive  Hib  disease
can  occur  due  to  vaccine  failure.
Efforts  to  keep  the  low  incidence  of  invasive  Hib  disease  should  be  directed  to
the  maintenance  of  high  vaccination  coverage  rates,  combined  with  the  notiﬁcation
and  surveillance  strategies  already  implemented  in  each  country.Please  cite  this  article  in  press  as:  Almeida  AF,  et  al.  Haemo
immunocompetent  child.  J  Infect  Public  Health  (2016),  http
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Table  1  White  blood  cells  count  and  C-reactive  pro-
tein  results.
Inpatient  day  D1  D2  D7
Leukocytes  (×109/L)  6.0  21.4  16.7
Neutrophils  (%)  53.8  79  26.7
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Introduction
Haemophilus  inﬂuenzae  is  a  gram  negative  coc-
cobacillus  which  can  be  capsulated  or  not.
According to  the  capsule  polysaccharide  compo-
sition it  is categorized  into  six  serotypes  (a—f)
[1].  The  serotype  b  (Hib)  is  the  most  virulent  and
the major  cause  of  bacterial  meningitis.  Until  the
1990s Hib  was  responsible  for  3 million  invasive
infections, worldwide,  which  resulted  in  386,000
deaths/year in  children  under  ﬁve  years  [1—3].
After the  introduction  of  Hib  vaccines  there  was
a dramatic  decrease  in  the  incidence  (41/100  000
in 1987  to  0.11/100  000  in  2007)  and  mortality  of
invasive  Hib  disease  in  all  ages  [2,3]. This  trend  was
also found  in  Portugal  [4]  since  2000,  with  the  intro-
duction  of  the  vaccine  in  the  routine  immunisation
schedule (RIS),  at  2,  4,  6  and  18  months  [5].
The European  Union  Invasive  Bacterial  Infections
Surveillance deﬁnes  true  vaccine  failure  (VF)  as  the
occurrence  of  invasive  Hib  disease  at  any  time  after
3 doses  of  vaccine  administered  during  the  ﬁrst  year
of life;  ≥2  weeks  after  one  dose  administered  after
12 months,  or  ≥1  week  after  ≥2  doses  administered
before 1  year  of  life  [6].
The incidence  of  vaccine  failure  is  rare
(0.2/100 000)  and  it  is  associated  with  the  pres-
ence of  comorbidities  (44%  of  cases  had  clinical  risk
factors and/or  deﬁcit  of  immunoglobulins)  [6—9].
Between 2002  and  2010,  only  ﬁve  cases  of  Hib  VF
were reported  in  Portugal  [4].
Case report
We  describe  a  case,  of  a  15-months-old  girl,  born
full term,  previously  healthy  and  vaccinated  with  3
doses of  a  Hib  vaccine  (Pentavac®,  Sanoﬁ  Pasteur
MSD) at  2,  4  and  6months  old.
She was  admitted  in  the  emergency  room  with
fever (39 ◦C  axillary  temperature),  food  vomiting
and progressive  deterioration  of  general  condition,
during the  previous  2  h.
On  physical  examination  she  was  irritable  and
constantly whining,  pale  and  dehydrated.  Brudzin-
ski’s sign  was  positive.  There  were  no  rash  or
petechiae and  the  remaining  exam  was  normal.
Analytical screening  was  performed:  blood  count
with platelet  and  biochemistry  showed  no  changes
and C-reactive  protein  (CRP)  was  within  the  normal
range  (11  mg/L).  The  urinalysis  was  normal.  A  lum-Please  cite  this  article  in  press  as:  Almeida  AF,  et  al.  Haemo
immunocompetent  child.  J  Infect  Public  Health  (2016),  http
bar puncture  was  performed:  cerebrospinal  ﬂuid
(CSF)  revealed  pleocytosis  (2900  cells/L),  with
a predominance  of  polymorphonuclear  neutrophils
(83%), high  protein  levels  (1.06  g/L)  and  normal  CSF
T
V
dCRP  (mg/L)  11.0  194.1  8.9
CRP, C-reactive protein.
lucose  (0.27  g/L).  Blood,  urine  and  CSF  were  sent
or culture.
Suspicion  of  bacterial  meningitis  triggered  hospi-
al admission,  droplet  isolation  and  empiric  intra-
enous antibiotics  (ceftriaxone  and  vancomycin).
In the  ﬁrst  24  h inﬂammatory  parameters
ncreased:  leukocytosis  (21.4  ×  109/L)  with  neu-
rophilia (79%)  and  elevated  CRP  (194  mg/L).
The  CSF  gram  stain  showed  a  gram-negative  coc-
obacillus,  Haemophilus  inﬂuenzae  strain.  Antimi-
robial  susceptibility  testing  showed  no  resistance
o ceftriaxone  and  then  vancomycin  was  stopped.
Bacteriological  exams  of  blood  and  urine  were
oth negative.
The serotyping  of  the  Haemophilus  inﬂuenzae
train was  performed  in  the  National  Reference
aboratory for  Bacterial  Respiratory  Infections  by
olymerase  chain  reaction  [10]  and  revealed  a
erotype b.
Favourable  clinical  outcome  was  achieved  and
aboratory  results  returned  to  normal  (Table  1).
After 10  days  of  intravenous  ceftriaxone  the
atient was  discharged  home  and  referred  to  the
eneral  Pediatrics  and  Otolaryngology  outpatient
linic.
Hib antibodies  concentration  was  not  measured
uring the  acute  phase  of  illness  because  recog-
ition of  this  Hib  strain  was  made  only  after
ischarge.
The child  had  the  vaccine  booster  dose  during
he second  year  of  life  (at  18  months),  according  to
he RIS.  Only  after  that  was  Hib  antibodies  concen-
ration  measured,  which  was  normal.
After  one  year  of  follow-up,  an  adequate
sychomotor  development  and  neurological  exam-
nation  as  well  as  a normal  immunological  status
immunoglobulins  and  complement  levels)  were
onﬁrmed.  The  auditory  evoked  potentials  were
ormal.
iscussionphilus  inﬂuenzae  type  b  meningitis  in  a  vaccinated  and
://dx.doi.org/10.1016/j.jiph.2016.06.001
his  case  typiﬁes  the  most  common  form  of  Hib
F found  in  literature  [6,8].  The  majority  of  the
escribed  cases  occurred  in  children  with  3  doses
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ib  meningitis  vaccine  failure  
f  vaccine  before  12  months  and  43%  in  children
ess than  2  years.  The  most  common  form  of  clinical
resentation was  meningitis  (44%)  [6].
It is recommended  for  all  cases  of  Hib  VF,  to  mea-
ure Hib  antibodies  concentration,  in  the  disease
onvalescent  period,  especially  in  children  under
8 months  of  age  and/or  with  associated  comor-
idities. If  convalescent  antibodies  concentration
s low,  a  booster  vaccine  dose  should  be  performed
6,9].  In  this  case  report,  vaccine  booster  was
dministered  on  a  scheduled  basis  at  18  months,
ccording to  our  RIS.  Hib  antibodies  concentration
as only  measured  afterwards  and  was  normal.
All Hib  VF  survivors  must  be  monitored,  since  1
n 7  healthy  children  and  more  than  2/3  of  chil-
ren with  morbidities,  will  develop  at  least  one
ther serious  infection,  requiring  hospital  admis-
ion  during  childhood  [11].  The  girl  described  had
o serious  complications  within  one  year  after  the
cute event.
In order  to  maintain  a  low  incidence  of  inva-
ive Hib  disease  two  different  strategies  have  been
escribed.  First  the  administration  of  a  vaccine
ooster dose  during  the  second  year  of  life  and/or
fter an  invasive  Hib  disease  infection  with  low
ib antibodies  concentration  or  without  antibod-
es measurement  available.  The  UK  and  Ireland
ntroduced it  at  13  month  of  age,  since  most  chil-
ren with  Hib  VF  that  received  3  doses  of  the
accine before  6  months,  developed  disease  at  least
 year  after  the  last  dose  [6,8,12]. In  Portugal  the
ooster  dose  is  administered  at  18  months  [5]. The
econd  strategy  considers  that  all  Hib  VF  survivors
hould have  an  additional  dose  of  vaccine  a few
ears after  infection,  with  the  intent  of  enhancing
he long-term  immunity  [9].  The  implementation  of
his strategy  will  require  additional  studies  to  prove
ts beneﬁt.
Despite  vaccination  compliance  and  absence  of
isk factors,  invasive  Hib  disease  can  occur  due  to
F, which  pathogenesis  is  not  entirely  clear  [6].
With current  global  Hib  vaccination  programs,
isease elimination  can  be  conceivable,  partic-
larly in  most  developed  settings.  Nevertheless
isease eradication  is  unlikely  because  of  Hib  nasal
arriage  in  healthy  population  and  VF.
Efforts  should  focus  on  keeping  high  vaccina-
ion coverage,  ensuring  good  quality  reporting
nd establishing  a  clear  protocol  for  booster  dose
dministration.Please  cite  this  article  in  press  as:  Almeida  AF,  et  al.  Haemo
immunocompetent  child.  J  Infect  Public  Health  (2016),  http
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